Categories: BrainDiagnosticsNews

Nexstim Plc’s Financial Information in 2023

Company Announcement, Helsinki, 23 December 2022 at 1 PM (EET)

Nexstim Plc’s Financial Information in 2023

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that it will publish the following financial information in 2023:

The 2022 Financial Statements Release and Half-Yearly Report July−December 2022 (H2) on Monday, February 27, 2023. Half-Yearly Report January-June 2023 (H1) on Friday, August 11, 2023.

Nexstim’s Annual Report 2022 will be published and available on the Company’s website on Monday, March 6, 2023.

The Annual General Meeting is tentatively scheduled to be held on Friday March 31, 2023 at 10:00 am.

NEXSTIM PLC        

Mikko Karvinen, CEO

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

The Company’s Certified Advisor is Erik Penser Bank.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com

Attachment

Staff

Recent Posts

Glow Lifetech Announces Expansion into Manitoba Market and Portfolio Expansion in New Brunswick, Advancing National Growth Strategy

Toronto, Ontario--(Newsfile Corp. - February 3, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF)…

9 minutes ago

Massimo Group Signs Letter of Intent to Acquire 100% of AI technology company FST in Drive to Accelerate Its AI-Powered Mobility and Health Technology Strategy

GARLAND, Texas, Feb. 3, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"),…

2 hours ago

Baysient Launches iDose® GEN7.0, Expanding Precision Dosing Platform to 16 Inflammatory Disease Indications

Next-Generation Decision Support Software Introduces Predictive Clinical Tools for Gastroenterology, Rheumatology, Dermatology, and PulmonologyFORT MYERS,…

2 hours ago

From the Founders of Fitbit: Introducing Luffu, Your Guardian for Family Health & Safety

After making personal health accessible to millions with Fitbit, James Park and Eric Friedman announce…

2 hours ago

Embla Medical hf: Interim Report Q4 and Full Year 2025

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full…

2 hours ago

UAE Partners with Colossal Biosciences to Protect Biodiversity and Champion the Future of Life on Earth

The collaboration positions the UAE as a global leader in conservation, driving pioneering initiatives in…

2 hours ago